ACP-105 — Dosing, Cycles, Half-Life & Side Effects
ACP-105 is a selective androgen receptor modulator (SARM) with a half-life of 4-6 hours. Partial agonist SARM with mild effects for lean mass and minimal suppression, based on preclinical data. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.
Quick Facts
| Class | Selective Androgen Receptor Modulator |
|---|---|
| Half-life | 4-6 hours |
| Aromatization | No |
| Hepatotoxicity | Low |
| Suppression | 3/10 |
| 17α-alkylated | No |
Typical Dosing Ranges
Common dose range: 5-10mg/day
Cycle length: 8-12 weeks
Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.
Stacking Considerations
- No structural stacking blockers. Standard harm-reduction rules apply: minimize total androgen load, minimize oral exposure, and monitor bloodwork.
PCT Requirements
- Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
- Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.
Side Effect Profile
- Limited human data
- Mild effects
- Short half-life
- Expensive
Known Interactions
No compound-specific interactions are catalogued in the current matrix. This does not mean no risk exists — it means there is no curated pairwise entry.
Related compounds
Monitoring (Bloodwork & Vitals)
- Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
- Lipid panel (total cholesterol, HDL, LDL, triglycerides)
- CBC (hemoglobin, hematocrit — watch for erythrocytosis)
- Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
- Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)
Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.
Frequently Asked Questions
What is the half-life of ACP-105?
ACP-105 has a half-life of approximately 4-6 hours. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.
What is the typical dose range for ACP-105?
Commonly reported ranges for ACP-105: 5-10mg/day. Cycle length: 8-12 weeks. These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.
Does ACP-105 suppress natural testosterone?
ACP-105 causes moderate suppression of the HPTA axis (score 3/10). PCT may still be advisable depending on stack and duration.
Is ACP-105 liver toxic?
Hepatotoxicity rating: Low. Non-17αα compound — liver stress is lower but still warrants periodic monitoring during a cycle.
Does ACP-105 aromatize to estrogen?
Aromatization profile: No. Minimal to no aromatization expected, so aromatase inhibitors are not typically indicated for this compound alone.
What is ACP-105 typically used for?
ACP-105 is commonly used for: First SARM cycle, Cutting, Women. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.
Citations
Disclaimer
StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use ACP-105. Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.